Vir Biotechnology宣布PSMA靶向Pro-Xten®双掩蔽T细胞接合器Vir-5500联合雄激素受体通路抑制剂治疗转移性前列腺癌的1期试验第3部分首位患者开始给药

美股速递
Oct 10, 2025

Vir Biotechnology宣布,其PSMA靶向Pro-Xten®双掩蔽T细胞接合器Vir-5500联合雄激素受体通路抑制剂治疗转移性前列腺癌的1期试验第3部分已完成首位患者给药。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10